Literature DB >> 18990089

High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.

Helena Carén1, Frida Abel, Per Kogner, Tommy Martinsson.   

Abstract

ALK (anaplastic lymphoma kinase) is oncogenic in several tumours and has recently been identified as a predisposition gene for familial NB (neuroblastoma) harbouring mutations in the TKD (tyrosine kinase domain). We have analysed a large set of sporadic human NB primary tumours of all clinical stages for chromosomal re-arrangements using a CGH (comparative genomic hybridization) array (n=108) and mutations of the ALK gene (n=90), and expression of ALK and related genes (n=19). ALK amplification or in-gene re-arrangements were found in 5% of NB tumours and mutations were found in 11%, including two novel not previously published mutations in the TKD, c.3733T>A and c.3735C>A. DNA mutations in the TKD and gene amplifications were only found in advanced large primary tumours or metastatic tumours, and correlated with the expression levels of ALK and downstream genes as well as other unfavourable features, and poor outcome. The results of the present study support that the ALK protein contributes to NB oncogenesis providing a highly interesting putative therapeutic target in a subset of unfavourable NB tumours.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990089     DOI: 10.1042/bj20081834

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  100 in total

1.  ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.

Authors:  Franck Bourdeaut; Sandrine Ferrand; Laurence Brugières; Marjorie Hilbert; Agnès Ribeiro; Ludovic Lacroix; Jean Bénard; Valérie Combaret; Jean Michon; Dominique Valteau-Couanet; Bertrand Isidor; Xavier Rialland; Maryline Poirée; Anne-Sophie Defachelles; Michel Peuchmaur; Gudrun Schleiermacher; Gaëlle Pierron; Marion Gauthier-Villars; Isabelle Janoueix-Lerosey; Olivier Delattre
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

2.  Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Authors:  Scott C Bresler; Andrew C Wood; Elizabeth A Haglund; Joshua Courtright; Lili T Belcastro; Jefferson S Plegaria; Kristina Cole; Yana Toporovskaya; Huaqing Zhao; Erica L Carpenter; James G Christensen; John M Maris; Mark A Lemmon; Yaël P Mossé
Journal:  Sci Transl Med       Date:  2011-11-09       Impact factor: 17.956

Review 3.  New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.

Authors:  Peter E Zage; Chrystal U Louis; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

Review 4.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

5.  ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.

Authors:  Katrien Van Roosbroeck; Jan Cools; Daan Dierickx; José Thomas; Peter Vandenberghe; Michel Stul; Jan Delabie; Chris De Wolf-Peeters; Peter Marynen; Iwona Wlodarska
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 6.  New insights into the genetics of neuroblastoma.

Authors:  Srishma Sridhar; Batool Al-Moallem; Hawra Kamal; Marta Terrile; Raymond L Stallings
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

7.  PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.

Authors:  Tiziana Bachetti; Daniela Di Paolo; Simona Di Lascio; Valentina Mirisola; Chiara Brignole; Marta Bellotti; Irene Caffa; Chiara Ferraris; Michele Fiore; Diego Fornasari; Roberto Chiarle; Silvia Borghini; Ulrich Pfeffer; Mirco Ponzoni; Isabella Ceccherini; Patrizia Perri
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

8.  Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes.

Authors:  Kaisa Thorell; Annika Bergman; Helena Carén; Staffan Nilsson; Per Kogner; Tommy Martinsson; Frida Abel
Journal:  BMC Med Genomics       Date:  2009-08-17       Impact factor: 3.063

9.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117

10.  Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma.

Authors:  Paola Scaruffi; Sara Stigliani; Stefano Moretti; Simona Coco; Carla De Vecchi; Francesca Valdora; Alberto Garaventa; Stefano Bonassi; Gian Paolo Tonini
Journal:  BMC Cancer       Date:  2009-12-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.